Log in to search using one of your social media accounts:

 

Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen
$780 Million Payment to be Funded From Joint Venture's Existing Cash Holdings Kyowa Hakko Kirin to Continue as Licensee in Asia THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Amgen and Kirin Holdings (Kirin) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen. Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGEN® (epoetin alfa). Over time, the sco...
Source: Amgen News Release - October 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

D.C. Week: CBO Still Sees Surge in Uninsured with AHCA
(MedPage Today) -- Also: FDA panel backs new breast cancer drug, Epogen biosimilar (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 27, 2017 Category: Dermatology Source Type: news

Epoetin Alfa Biosimilar Clears FDA Hurdle
(MedPage Today) -- Near-unanimous support from advisory committee (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 25, 2017 Category: American Health Source Type: news

FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen ® / Procrit® across all indications
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee. (Source: World Pharma News)
Source: World Pharma News - May 25, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Epogen (Epoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 27, 2017 Category: Drugs & Pharmacology Source Type: news

EPREX ® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
French Health Authority ANSM grants approval in the Mutual Recognition Procedure; the relevant health authorities are required to implement the new indication within 30 days (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 24, 2017 Category: Pharmaceuticals Source Type: news

Amgen And DaVita Enter Into New Sourcing And Supply Agreement
THOUSAND OAKS, Calif., Jan. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has entered into a six-year Sourcing and Supply Agreement with DaVita Inc.  This is a continuation of Amgen's long-term relationship with DaVita that is focused on serving dialysis patients. Under the terms of the new agreement, Amgen will supply DaVita with EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto...
Source: Amgen News Release - January 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Procrit (Epoetin Alfa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 13, 2016 Category: Drugs & Pharmacology Source Type: news

Why Your Oncologist Might Prescribe Procrit or...
Learn why doctors prescribe Procrit and Aranesp to boost red cell production in breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 18, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

How are Procrit & Aranesp Used to Treat...
Procrit and Aranesp help boost red cell production for breast cancer patients who have anemia after undergoing chemotherapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 28, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Hospira Submits Biologics License Application to FDA
The application was for a proposed epoetin alfa biosimilar (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 12, 2015 Category: Pharmaceuticals Source Type: news

Express Scripts Drops Amgen Anemia Drugs From FormularyExpress Scripts Drops Amgen Anemia Drugs From Formulary
Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Express Scripts drops Amgen anemia drugs from formulary
(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Cancer Doctors Bill Big for Tarnished Drug
Many oncologists now use a drug called Procrit sparingly, after regulators raised concerns about it. One group of Florida doctors stands out for how much it bills Medicare for the pricey drug. (Source: WSJ.com: Health)
Source: WSJ.com: Health - June 20, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Cancer Doctors Ring Up Big Bills for Tarnished Drug
Many oncologists now use a drug called Procrit sparingly, after regulators raised concerns about it. One group of Florida doctors stands out for how much it bills Medicare for the pricey drug. (Source: WSJ.com: Health)
Source: WSJ.com: Health - June 20, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - April 29, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Epoetin Alfa Market & Erythropoietin Industry in China 2018...
ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Epoetin Alfa Market, 2009-2018” to its store.(PRWeb March 11, 2014)Read the full story at http://www.prweb.com/releases/2018-china-epoetin-alfa/epo-industry-report/prweb11658217.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 13, 2014 Category: Pharmaceuticals Source Type: news

Anemia in breast cancer patients reduced by epoetin alfa with no negative impact on survival
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published in the Journal of the National Cancer Institute. To investigate the safety and efficacy of epoetin alfa, Volker Moebus, M.D... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Epoetin alfa reduces anemia in breast cancer patients with no negative impact on survival
(Journal of the National Cancer Institute) In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free or overall survival. However, it can increase the risk of thrombotic events, according to a study published July 17 in the Journal of the National Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2013 Category: Cancer & Oncology Source Type: news

Procrit - Epoetin Alfa – Drug To Boost...
Procrit is a man-made protein, given as a booster shot to help restart red blood cell production when chemotherapy for breast cancer causes anemia. Procrit is a very safe drug, and has few risks and side effects. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - July 7, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Amgen Fraud Suit to Proceed as Class-Action
The U.S. Supreme Court shot down an effort by Epogen-maker Amgen to disqualify a securities fraud case as a class-action suit, sending the claims back to a lower court. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 27, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa. ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news